Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
28.26
+0.78 (2.84%)
May 4, 2026, 4:00 PM EDT - Market closed
Oculis Holding AG Revenue
In the year 2025, Oculis Holding AG had annual revenue of 1.20M CHF with 74.78% growth. Oculis Holding AG had revenue of 411.00K in the quarter ending December 31, 2025, with 13,600.00% growth.
Revenue (ttm)
1.20M CHF
Revenue Growth
+74.78%
P/S Ratio
1,105.85
Revenue / Employee
19,983 CHF
Employees
60
Market Cap
1.67B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Innoviva | 411.33M |
| Syndax Pharmaceuticals | 217.17M |
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Agios Pharmaceuticals | 66.05M |
| Nuvation Bio | 62.90M |
| Nanobiotix | 38.27M |
OCS News
- 3 days ago - Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - GlobeNewsWire
- 13 days ago - Oculis Publishes Invitation to the Annual General Meeting - GlobeNewsWire
- 14 days ago - Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 20 days ago - Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 26 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 27 days ago - Oculis to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - GlobeNewsWire
- 7 weeks ago - Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - GlobeNewsWire